alexa Abstract | Theoretical study on physicochemical and geometrical properties of Doxorubicin and Daunorubicin conjugated to PEO-b-PCL nanoparticles

European Journal of Experimental Biology
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article Open Access


Daunorubicin (or daunomycin) and Doxorubicin (or adriamycin or 14-hydroxydaunomycin) are well-known anticancer agents used in cancer chemotherapy. They are anthracycline antibiotics and are commonly used in the treatment of a wide range of cancers. Doxorubicin and Daunorubicin were chemically conjugated to PEO-b-PCL (poly(ethylene oxide)-block-poly(-caprolactone)) nanoparticles. In this research, the molecular structure, Binding Energy(BE), Dipole Moment (DM), Gibbs free energy of solvation (ΔG (solvation)) and some physicochemical properties of the Doxorubicin- PEO-b-PCL and Daunorubicin- PEO-b-PCL were investigated. Our results indicate that these complexes mentioned above can be used to improve the anti-cancer activity.

To read the full article Peer-reviewed Article PDF image

Author(s): S Bagheri S M Hassani and Gh Naderi


Anti-cancer drugs, Molecular geometry, Doxorubicin, Daunorubicin, PEO-b-PCL nanoparticles

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version